TESO
Tesofensine
Not a peptide. A small-molecule phenyltropane that inhibits the presynaptic transporters for three monoamines — serotonin, noradrenaline and dopamine — so it belongs to an entirely different pharmacological class from the receptor agonists it is grouped with here.
Tesofensine has 11 registered human studies on ClinicalTrials.gov, reaching phase 2, covering 1,215 planned or enrolled participants across the 11 studies that published a figure. No FDA-approved product contains Tesofensine. 9 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Tesofensine; the registry search is fuzzy, so every match is re-checked. None of this says whether Tesofensine works or is safe.
FDA status
Research only
Human studies
11
Furthest phase
Phase 2
Papers, 10 yr
9
Readership
3,235
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
11
Registered human studies
Phase 2
Furthest phase reached
1,215
Planned or enrolled participants, across 11 studies that published a figure
None
No FDA-approved product contains it
13 loose registry matches were checked and 11 confirmed — 2 named something else and were discarded. We count a study only when Tesofensine is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Tesofensine is, and what it has been studied for
Tesofensine is classified by ChEMBL as a small molecule, and appears in trial registrations under NS 2330 and NS-2330. Its FDA substance identifier is BLH9UKX9V1.
Across 11 registered trials, it has been studied in Obesity, Hypothalamic Injury-induced Obesity (HIO), Alzheimer Disease and Type 2 Diabetes Mellitus. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Saniona and NeuroSearch A/S among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Tesofensine reached Phase 2 across 11 registered trials.
No FDA-approved product contains Tesofensine. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Tesofensine?
Papers published each year that name Tesofensine in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 2 | Yes |
| 2018 | 2 | 0 | Yes |
| 2019 | 1 | 1 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 0 | 2 | Yes |
| 2022 | 1 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 2 | 0 | Yes |
| 2026 | 1 | 0 | No |
9 papers and 5 registered trials between 2017 and 2026. A paper counts when “Tesofensine” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Tesofensine
9 indexed papers name Tesofensine in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Tesofensine and weight loss
- Tesofensine and weight loss
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons
- Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
- Structural basis for pharmacotherapeutic action of triple reuptake inhibitors
- Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat
- Under-reporting of adverse effects of tesofensine
Collected 2026-08-02from PubMed, phrase-matched on “Tesofensine” in title and abstract. Run the same search.
About Tesofensine
Not a peptide. A small-molecule phenyltropane that inhibits the presynaptic transporters for three monoamines — serotonin, noradrenaline and dopamine — so it belongs to an entirely different pharmacological class from the receptor agonists it is grouped with here.
- Also known as
- NS2330
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.